{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:45:52Z","timestamp":1791287152445,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012943","name":"Institut national de la recherche scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017653","name":"Fonds Sp\u00e9ciaux de Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016132","name":"Gouvernement Wallon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002749","name":"Belgian Federal Science Policy Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002749","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004936","name":"Direction G\u00e9n\u00e9rale des Infrastructures, des Transports et de la Mer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004936","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008573","name":"Cement Association of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004965","name":"Sixth Framework Programme","doi-asserted-by":"publisher","award":["INCA LSHC-CT-2005-018704"],"award-info":[{"award-number":["INCA LSHC-CT-2005-018704"]}],"id":[{"id":"10.13039\/501100004965","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.lungcan.2013.05.014","type":"journal-article","created":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T11:46:45Z","timestamp":1371556005000},"page":"311-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["The role of epigenetics in malignant pleural mesothelioma"],"prefix":"10.1016","volume":"81","clinical-trial-number":[{"clinical-trial-number":"nct00019825","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00020579","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00037817","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00128102","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00365053","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00413322","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00535951","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00634205","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01353482","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Fabian","family":"Vandermeers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathya","family":"Neelature Sriramareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrisostome","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Hubaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Cosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2013.05.014_bib0005","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br J Ind Med"},{"issue":"3","key":"10.1016\/j.lungcan.2013.05.014_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/CEJ.0b013e32834dbc56","article-title":"Role of stopping exposure and recent exposure to asbestos in the risk of mesothelioma","volume":"21","author":"La Vecchia","year":"2012","journal-title":"Eur J Cancer Prev"},{"issue":"3\u20134","key":"10.1016\/j.lungcan.2013.05.014_bib0015","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","article-title":"The European mesothelioma epidemic","volume":"79","author":"Peto","year":"1999","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2013.05.014_bib0020","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/aje\/kwh279","article-title":"Re: \u201cMesothelioma trends in the United States: an update based on surveillance, epidemiology, and end results program data for 1973 through 2003\u201d","volume":"160","author":"Lange","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.lungcan.2013.05.014_bib0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2486\/indhealth.39.65","article-title":"Asbestos-related lung cancer and mesothelioma in Japan","volume":"39","author":"Morinaga","year":"2001","journal-title":"Ind Health"},{"issue":"2","key":"10.1016\/j.lungcan.2013.05.014_bib0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/aje\/kwh025","article-title":"Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003","volume":"159","author":"Price","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.lungcan.2013.05.014_bib0035","article-title":"An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma","author":"Pasello","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"14","key":"10.1016\/j.lungcan.2013.05.014_bib0040","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.lungcan.2013.05.014_bib0045","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2\u20133","key":"10.1016\/j.lungcan.2013.05.014_bib0050","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0169-5002(00)00166-5","article-title":"Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B","volume":"31","author":"Kindler","year":"2001","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2013.05.014_bib0055","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2013.05.014_bib0060","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S","article-title":"A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group","volume":"85","author":"van Meerbeeck","year":"1999","journal-title":"Cancer"},{"issue":"1235","key":"10.1016\/j.lungcan.2013.05.014_bib0065","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1098\/rstb.1990.0015","article-title":"DNA methylation and epigenetic inheritance","volume":"326","author":"Holliday","year":"1990","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"3","key":"10.1016\/j.lungcan.2013.05.014_bib0070","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0092-8674(00)81958-3","article-title":"Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome","volume":"98","author":"Kornberg","year":"1999","journal-title":"Cell"},{"issue":"6648","key":"10.1016\/j.lungcan.2013.05.014_bib0075","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/38444","article-title":"Crystal structure of the nucleosome core particle at 2.8 A resolution","volume":"389","author":"Luger","year":"1997","journal-title":"Nature"},{"issue":"6067","key":"10.1016\/j.lungcan.2013.05.014_bib0080","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/321209a0","article-title":"CpG-rich islands and the function of DNA methylation","volume":"321","author":"Bird","year":"1986","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.lungcan.2013.05.014_bib0085","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/ng0794-376","article-title":"The distribution of CpG islands in mammalian chromosomes","volume":"7","author":"Craig","year":"1994","journal-title":"Nat Genet"},{"issue":"1\u20133","key":"10.1016\/j.lungcan.2013.05.014_bib0090","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejphar.2009.10.011","article-title":"Epigenetics and cancer treatment","volume":"625","author":"Kristensen","year":"2009","journal-title":"Eur J Pharmacol"},{"issue":"16","key":"10.1016\/j.lungcan.2013.05.014_bib0095","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1128\/MCB.23.16.5594-5605.2003","article-title":"Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b","volume":"23","author":"Chen","year":"2003","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.lungcan.2013.05.014_bib0100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0092-8674(00)81656-6","article-title":"DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development","volume":"99","author":"Okano","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2013.05.014_bib0105","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1073\/pnas.51.5.786","article-title":"Acetylation and methylation of histones and their possible role in the regulation of rna synthesis","volume":"51","author":"Allfrey","year":"1964","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.lungcan.2013.05.014_bib0110","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0021-9258(18)54150-8","article-title":"Studies of the DNA binding properties of histone H4 amino terminus. Thermal denaturation studies reveal that acetylation markedly reduces the binding constant of the H4 \u201ctail\u201d to DNA","volume":"268","author":"Hong","year":"1993","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.lungcan.2013.05.014_bib0115","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0092-8674(89)90920-3","article-title":"Histone acetylation reduces nucleosome core particle linking number change","volume":"57","author":"Norton","year":"1989","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.lungcan.2013.05.014_bib0120","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.1128\/MCB.00742-07","article-title":"Regulation of gene transcription by the histone H2A N-terminal domain","volume":"27","author":"Parra","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.lungcan.2013.05.014_bib0125","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1073\/pnas.55.4.805","article-title":"RNA synthesis and histone acetylation during the course of gene activation in lymphocytes","volume":"55","author":"Pogo","year":"1966","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.lungcan.2013.05.014_bib0130","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/nar\/5.6.1863","article-title":"DNA associated with hyperacetylated histone is preferentially digested by DNase I","volume":"5","author":"Sealy","year":"1978","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"10.1016\/j.lungcan.2013.05.014_bib0135","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.tig.2003.09.007","article-title":"Histone lysine methylation: a signature for chromatin function","volume":"19","author":"Sims","year":"2003","journal-title":"Trends Genet"},{"issue":"1","key":"10.1016\/j.lungcan.2013.05.014_bib0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1074-5521(02)00092-3","article-title":"Deacetylase enzymes: biological functions and the use of small-molecule inhibitors","volume":"9","author":"Grozinger","year":"2002","journal-title":"Chem Biol"},{"issue":"3","key":"10.1016\/j.lungcan.2013.05.014_bib0145","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat Rev Cancer"},{"issue":"Pt 3","key":"10.1016\/j.lungcan.2013.05.014_bib0150","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.lungcan.2013.05.014_bib0155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1749-6632.2010.05893.x","article-title":"The epigenetic landscape of addiction","volume":"1216","author":"Maze","year":"2011","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"10.1016\/j.lungcan.2013.05.014_bib0160","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.lungcan.2013.05.014_bib0165","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ng.159","article-title":"Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation","volume":"40","author":"Kondo","year":"2008","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.lungcan.2013.05.014_bib0170","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/j.1460-2075.1995.tb07078.x","article-title":"Chromosome condensation induced by fostriecin does not require p34cdc2 kinase activity and histone H1 hyperphosphorylation, but is associated with enhanced histone H2A and H3 phosphorylation","volume":"14","author":"Guo","year":"1995","journal-title":"EMBO J"},{"issue":"11","key":"10.1016\/j.lungcan.2013.05.014_bib0175","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.tibs.2010.05.006","article-title":"Fast signals and slow marks: the dynamics of histone modifications","volume":"35","author":"Barth","year":"2010","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.lungcan.2013.05.014_bib0180","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1146\/annurev.pharmtox.45.120403.095832","article-title":"Aberrant DNA methylation as a cancer-inducing mechanism","volume":"45","author":"Esteller","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.lungcan.2013.05.014_bib0185","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrc1279","article-title":"The history of cancer epigenetics","volume":"4","author":"Feinberg","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2013.05.014_bib0190","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s00018-010-0624-z","article-title":"Epigenetic aberrations during oncogenesis","volume":"68","author":"Hatziapostolou","year":"2011","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"10.1016\/j.lungcan.2013.05.014_bib0195","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1593\/neo.10290","article-title":"Tumor-initiating and -propagating cells: cells that we would like to identify and control","volume":"12","author":"Tysnes","year":"2010","journal-title":"Neoplasia"},{"issue":"16","key":"10.1016\/j.lungcan.2013.05.014_bib0200","first-page":"3347","article-title":"Methylation of the BRCA1 gene in sporadic breast cancer","volume":"57","author":"Dobrovic","year":"1997","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.lungcan.2013.05.014_bib0205","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/carcin\/bgl033","article-title":"The necessity of a human epigenome project","volume":"27","author":"Esteller","year":"2006","journal-title":"Carcinogenesis"},{"issue":"21","key":"10.1016\/j.lungcan.2013.05.014_bib0210","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1056\/NEJMra023075","article-title":"Gene silencing in cancer in association with promoter hypermethylation","volume":"349","author":"Herman","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lungcan.2013.05.014_bib0215","first-page":"880","article-title":"Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene","volume":"48","author":"Sakai","year":"1991","journal-title":"Am J Hum Genet"},{"issue":"10","key":"10.1016\/j.lungcan.2013.05.014_bib0220","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.4161\/cc.4.10.2113","article-title":"Towards the human cancer epigenome: a first draft of histone modifications","volume":"4","author":"Fraga","year":"2005","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.lungcan.2013.05.014_bib0225","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pros.20022","article-title":"Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer","volume":"59","author":"Halkidou","year":"2004","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.lungcan.2013.05.014_bib0230","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.phrs.2010.02.010","article-title":"Histone deacetylases and epigenetic therapies of hematological malignancies","volume":"62","author":"Mercurio","year":"2010","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.lungcan.2013.05.014_bib0235","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-0463.2005.apm_04.x","article-title":"Increased expression of histone deacetylase 2 is found in human gastric cancer","volume":"113","author":"Song","year":"2005","journal-title":"APMIS"},{"issue":"1","key":"10.1016\/j.lungcan.2013.05.014_bib0240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10549-005-6001-1","article-title":"Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast","volume":"94","author":"Zhang","year":"2005","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.lungcan.2013.05.014_bib0245","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ijc.2910390104","article-title":"Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey","volume":"39","author":"Baris","year":"1987","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2013.05.014_bib0250","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/01913129709021929","article-title":"Malignant mesothelioma: current conundrums over risk estimates and whither electron microscopy for diagnosis?","volume":"21","author":"Comin","year":"1997","journal-title":"Ultrastruct Pathol"},{"issue":"3","key":"10.1016\/j.lungcan.2013.05.014_bib0255","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3816\/CLC.2003.n.031","article-title":"Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40","volume":"5","author":"Gazdar","year":"2003","journal-title":"Clin Lung Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2013.05.014_bib0260","first-page":"2263","article-title":"Cigarette smoking, asbestos exposure, and malignant mesothelioma","volume":"51","author":"Muscat","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2013.05.014_bib0265","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-642-10862-4_5","article-title":"Pathohistological diagnosis and differential diagnosis","volume":"189","author":"Tischoff","year":"2011","journal-title":"Recent Results Cancer Res"},{"issue":"3","key":"10.1016\/j.lungcan.2013.05.014_bib0270","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/oxfordjournals.aje.a009093","article-title":"Analysis of current trends in United States mesothelioma incidence","volume":"145","author":"Price","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"28","key":"10.1016\/j.lungcan.2013.05.014_bib0275","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.lungcan.2013.05.014_bib0280","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/jnci\/95.8.598","article-title":"Using gene expression ratios to predict outcome among patients with mesothelioma","volume":"95","author":"Gordon","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.lungcan.2013.05.014_bib0285","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0002-9440(10)62492-3","article-title":"Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling","volume":"166","author":"Gordon","year":"2005","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.lungcan.2013.05.014_bib0290","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-08-2586","article-title":"Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome","volume":"69","author":"Christensen","year":"2009","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.lungcan.2013.05.014_bib0295","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1158\/0008-5472.CAN-09-1595","article-title":"Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma","volume":"69","author":"Goto","year":"2009","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.lungcan.2013.05.014_bib0300","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/carcin\/bgn059","article-title":"Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma","volume":"29","author":"Christensen","year":"2008","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.lungcan.2013.05.014_bib0305","first-page":"423","article-title":"Aberrant promoter methylation of WIF-1 and SFRP1, 2, 4 genes in mesothelioma","volume":"24","author":"Kohno","year":"2010","journal-title":"Oncol Rep"},{"issue":"15","key":"10.1016\/j.lungcan.2013.05.014_bib0310","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1158\/1078-0432.CCR-10-3040","article-title":"Epigenetic silencing of microRNA-34b\/c plays an important role in the pathogenesis of malignant pleural mesothelioma","volume":"17","author":"Kubo","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.lungcan.2013.05.014_bib0315","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.lungcan.2009.01.015","article-title":"Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells","volume":"66","author":"Amatori","year":"2009","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2013.05.014_bib0320","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jtcvs.2005.05.022","article-title":"Depletion of DNA methyltransferase 1 and\/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells","volume":"131","author":"Kassis","year":"2006","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"8","key":"10.1016\/j.lungcan.2013.05.014_bib0325","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.4161\/epi.6.8.16074","article-title":"The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma","volume":"6","author":"Nelson","year":"2011","journal-title":"Epigenetics"},{"issue":"13","key":"10.1016\/j.lungcan.2013.05.014_bib0330","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2013.05.014_bib0335","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2006.06.017","article-title":"Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma","volume":"54","author":"Fischer","year":"2006","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2013.05.014_bib0340","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.lungcan.2007.06.015","article-title":"DNA methylation profile of 28 potential marker loci in malignant mesothelioma","volume":"58","author":"Tsou","year":"2007","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2013.05.014_bib0345","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.ejmech.2010.02.030","article-title":"Inside HDAC with HDAC inhibitors","volume":"45","author":"Bertrand","year":"2010","journal-title":"Eur J Med Chem"},{"issue":"2","key":"10.1016\/j.lungcan.2013.05.014_bib0350","first-page":"166","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am J Transl Res"},{"issue":"4","key":"10.1016\/j.lungcan.2013.05.014_bib0355","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrd772","article-title":"Histone-deacetylase inhibitors: novel drugs for the treatment of cancer","volume":"1","author":"Johnstone","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.lungcan.2013.05.014_bib0360","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2011-2970","article-title":"Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells","author":"Catalano","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.lungcan.2013.05.014_bib0365","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.surg.2011.07.001","article-title":"Histone deacetylase inhibitors enhance endothelial cell sprouting angiogenesis in vitro","volume":"150","author":"Jin","year":"2011","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.lungcan.2013.05.014_bib0370","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2176\/nmc.52.186","article-title":"Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain","volume":"52","author":"Osuka","year":"2012","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"19","key":"10.1016\/j.lungcan.2013.05.014_bib0375","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1073\/pnas.0702294104","article-title":"Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma","volume":"104","author":"Lindemann","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"10.1016\/j.lungcan.2013.05.014_bib0380","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.ejca.2009.06.024","article-title":"The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation","volume":"45","author":"Carlisi","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2013.05.014_bib0385","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbrc.2003.12.074","article-title":"Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation","volume":"314","author":"Neuzil","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"10.1016\/j.lungcan.2013.05.014_bib0390","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1158\/1535-7163.MCT-09-0138","article-title":"The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer","volume":"8","author":"Crisanti","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.lungcan.2013.05.014_bib0395","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/JTO.0b013e318194f991","article-title":"A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL","volume":"4","author":"Symanowski","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.lungcan.2013.05.014_bib0400","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1165\/ajrcmb.25.5.4539","article-title":"Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma","volume":"25","author":"Cao","year":"2001","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"8","key":"10.1016\/j.lungcan.2013.05.014_bib0405","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.cgt.7700332","article-title":"Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma","volume":"8","author":"Mohiuddin","year":"2001","journal-title":"Cancer Gene Ther"},{"issue":"8","key":"10.1016\/j.lungcan.2013.05.014_bib0410","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1158\/1078-0432.CCR-08-1579","article-title":"Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma","volume":"15","author":"Vandermeers","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.lungcan.2013.05.014_bib0415","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2011.05.149","article-title":"Lovastatin and valproic acid additively attenuate cell invasion in ACC-MESO-1 cells","volume":"410","author":"Yamauchi","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.lungcan.2013.05.014_bib0420","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.lungcan.2010.10.016","article-title":"Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma","volume":"71","author":"Amatori","year":"2011","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2013.05.014_bib0425","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1158\/1078-0432.CCR-10-2986","article-title":"Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts","volume":"17","author":"Takenouchi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2013.05.014_bib0430","doi-asserted-by":"crossref","DOI":"10.1111\/j.1582-4934.2012.01584.x","article-title":"Epigallocatechin-3-gallate induces mesothelioma cell death via H(2) o(2) -dependent T-type Ca(2+) channel opening","author":"Ranzato","year":"2012","journal-title":"J Cell Mol Med"},{"issue":"1\u20132","key":"10.1016\/j.lungcan.2013.05.014_bib0435","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11010-011-0878-2","article-title":"Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis","volume":"357","author":"Wang","year":"2011","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.lungcan.2013.05.014_bib0440","doi-asserted-by":"crossref","DOI":"10.1002\/ptr.4645","article-title":"Curcumin Induces Autophagy in ACC-MESO-1 Cells","author":"Yamauchi","year":"2012","journal-title":"Phytother Res"},{"issue":"6","key":"10.1016\/j.lungcan.2013.05.014_bib0445","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.bjc.6600174","article-title":"Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications","volume":"86","author":"Sigalotti","year":"2002","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2013.05.014_bib0450","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00002371-200103000-00010","article-title":"Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1","volume":"24","author":"Weiser","year":"2001","journal-title":"J Immunother"},{"issue":"5","key":"10.1016\/j.lungcan.2013.05.014_bib0455","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1183\/09031936.00081310","article-title":"A 5-aza-2\u2032-deoxycytidine\/valproate combination induces cytotoxic T-cell response against mesothelioma","volume":"38","author":"Leclercq","year":"2011","journal-title":"Eur Respir J"},{"issue":"33","key":"10.1016\/j.lungcan.2013.05.014_bib0460","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1016\/j.vaccine.2011.05.029","article-title":"Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth","volume":"29","author":"Guillot","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.lungcan.2013.05.014_bib0465","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/eji.201141800","article-title":"Downregulation of MUC1 expression and its recognition by CD8(+) T cells on the surface of malignant pleural mesothelioma cells treated with HDACi","volume":"42","author":"Roulois","year":"2012","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.lungcan.2013.05.014_bib0470","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/JTO.0b013e318191520c","article-title":"Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma","volume":"4","author":"Ramalingam","year":"2009","journal-title":"J Thorac Oncol"},{"issue":"17","key":"10.1016\/j.lungcan.2013.05.014_bib0475","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2005.02.188","article-title":"Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma","volume":"23","author":"Ryan","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.lungcan.2013.05.014_bib0480","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3816\/CLC.2006.n.003","article-title":"Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid","volume":"7","author":"Krug","year":"2006","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2013.05.014_bib0485","doi-asserted-by":"crossref","first-page":"e52753","DOI":"10.1371\/journal.pone.0052753","article-title":"Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression","volume":"7","author":"Barbone","year":"2012","journal-title":"PloS ONE"},{"issue":"18S","key":"10.1016\/j.lungcan.2013.05.014_bib0490","first-page":"18088","article-title":"Phase I trial of vorinostat (V) in combination with pemetrexed (Pem) and cisplatin (CDDP) in patients with advanced cancer","volume":"25","author":"NJV","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2013.05.014_bib0495","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1183\/09031936.00037310","article-title":"Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study","volume":"37","author":"Scherpereel","year":"2011","journal-title":"Eur Respir J"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500213002262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500213002262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:30:29Z","timestamp":1770280229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500213002262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0169500213002262"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2013.05.014","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of epigenetics in malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2013.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}